Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Arunchai Chang has a total of 90 co-authors. Here are the top co-authors by number of shared publications:

  • Keerati Akarapatima

    Division of Gastroenterology, Department of Internal Medicine, Hatyai Hospital, Songkhla, Thailand

    10 shared publications
  • Attapon Rattanasupar

    Division of Gastroenterology, Department of Internal Medicine, Hatyai Hospital, Songkhla, Thailand

    9 shared publications
  • Varayu Prachayakul

    Siriraj Gastrointestinal Endoscopy Center, Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand

    7 shared publications
  • Varayu Prachayakul

    Siriraj Gastrointestinal Endoscopy Center, Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

    7 shared publications
  • Attapon Rattanasupa

    6 shared publications
  • Kittiphan Chienwichai

    Division of Nephrology, Department of Internal Medicine, Hatyai Hospital, Songkhla, Thailand

    6 shared publications

Latest Publications

  • Open Access

    Diagnostic Yield and Cost of Morphology-Guided Immunohistochemistry in Liver Tumors

    by Cheep Charoenlap, Pakorn Arunsawat, Tanaporn Prateepchaiboon, Kittiphan Chienwichai, Arunchai Chang

    Background: In many routine pathology settings, particularly where resources are constrained, liver tumors are evaluated with an individualized, morphology-guided immunohistochemistry (IHC) strategy rather than fixed panels or molecular assays. Despite widespread use, the real-world diagnostic yield, stain utilization, and laboratory cost of this approach are not well defined. Methods: We retrospectively reviewed consecutive malignant liver tumor diagnoses at a university-affiliated hospital from January 2020 to December 2023. Cases were classified as primary liver cancers or metastatic tumors. IHC was performed using a morphology-guided, case-based sequence. Primary outcomes were histologic subtype assignment among primary liver cancers and determination of the primary site among liver metastases. Secondary outcomes were IHC stain utilization and laboratory cost per case. Results: Among 279 malignant liver tumors, 144 (51.6%) were primary and 135 (48.4%) were metastatic. Hepatocellular carcinoma accounted for 80.6% of primary liver cancers. Among metastases, a likely primary site was identified in most cases; colorectal (31.1%), lung (9.6%), and pancreatic (8.1%) primaries were most common, while cancers of unknown primary comprised 14.8%. IHC utilization was lower in primary tumors than in metastases (median 2 stains/case [IQR 2–4] vs 4 stains/case [IQR 2–7]; p<0.001). Correspondingly, median laboratory IHC cost per case was lower for primary tumors than for metastases (USD 29.90 [IQR 21.73–51.00] vs USD 46.92 [IQR 21.73–92.57]; p<0.001). Conclusions: An individualized, morphology-guided IHC strategy enabled reliable subtyping of primary liver cancers and identification of likely primary sites for most liver metastases while maintaining compact stain utilization and moderate laboratory costs. These data provide practical, real-world benchmarks for diagnostic performance and resource use and support targeted, hypothesis-driven IHC where broad fixed panels or molecular diagnostics are not routinely available.

  • Open Access

    Impact of Helicobacter pylori Infection on Short-Term Outcomes in Acute Non-Variceal Upper Gastrointestinal Bleeding

    by Araya Khaimook, Kittiphan Chienwichai, Arunchai Chang

    Background: The clinical significance of Helicobacter pylori (H. pylori) infection in acute non-variceal upper gastrointestinal bleeding (NVUGIB) remains uncertain, particularly regarding short-term outcomes beyond rebleeding. Methods: We conducted a single-center retrospective cohort study of consecutive adults admitted with acute NVUGIB to Hatyai Hospital, Thailand, between January 2016 and December 2020. H. pylori status was determined during the index hospitalization using rapid urease testing and/or histopathologic examination of gastric biopsy specimens obtained during upper gastrointestinal endoscopy. The primary outcome was 30-day all-cause mortality. Secondary outcomes included in-hospital mortality, rebleeding, requirement of packed red blood cell transfusion, and length of hospital stay. Multivariable regression analyses were performed to adjust for potential confounders. Results: Among 933 patients, 289 (31.0%) were H. pylori-positive and 644 (69.0%) were H. pylori-negative. The H. pylori-positive group was younger, predominantly male, and had lower rates of cirrhosis and prior proton pump inhibitor use. They also more often had peptic ulcer bleeding and underwent earlier endoscopy. H. pylori positivity was independently associated with lower 30-day mortality (adjusted odds ratio 0.39, 95% confidence interval 0.18–0.84), but not with rebleeding, requirement of transfusion, or length of stay. Conclusions: H. pylori positivity was associated with lower short-term mortality in acute NVUGIB, although this finding may reflect baseline clinical differences rather than a direct effect on bleeding severity.

  • Open Access

    Association between a 24-h increase in blood urea nitrogen and clinical outcomes in acute non-variceal upper gastrointestinal bleeding: a dual-center retrospective cohort study

    by Kanit Bunnag, Arunchai Chang, Weeraporn Chuaypetch, Nataree Rujipattanapong, Kittiphan Chienwichai, Manus Rugivarodom, Sakkarin Chirapongsathorn, Varayu Prachayakul

    Background and aim: Blood urea nitrogen (BUN) is incorporated into admission-based risk scores for acute non-variceal upper gastrointestinal bleeding (NVUGIB); however, the clinical relevance of early in-hospital BUN kinetics remains unclear. Objectives: To evaluate whether a 24-h increase in BUN is independently associated with adverse clinical outcomes in patients with acute NVUGIB. Design: Dual-center retrospective cohort study. Methods: We conducted a dual-center retrospective cohort study of adult patients with endoscopically confirmed NVUGIB admitted between 2018 and 2023. The exposure was defined as any absolute increase in BUN within 18–30 h after the baseline measurement at presentation. The primary outcome was 30-day all-cause mortality. Secondary outcomes included in-hospital mortality, in-hospital rebleeding, red blood cell transfusion, length of hospital stay, and need for radiologic or surgical intervention. Multivariable regression was performed in a propensity score-matched cohort with confirmatory analyses in the original cohort. Results: Among 611 patients, 218 (35.7%) demonstrated a 24-h increase in BUN. Propensity score matching yielded 400 patients (200 per group). In the matched cohort, a 24-h BUN increase was independently associated with higher 30-day mortality (adjusted odds ratio (aOR) 3.307; 95% confidence interval (CI) 1.604–6.819) and in-hospital mortality (aOR 2.732; 95% CI 1.208–6.178). No independent associations were observed with rebleeding, transfusion requirements, or radiologic/surgical intervention. Conclusion: An increase in BUN within the first 24 h of hospitalization is independently associated with higher short-term mortality in acute NVUGIB. Early BUN kinetics may serve as a complementary risk marker, but prospective validation and formal predictive-performance testing are needed before clinical integration.

  • Open Access

    Association of pre-endoscopic fresh frozen plasma transfusion with clinical outcomes in patients with acute upper gastrointestinal bleeding and mild coagulopathy: a two-center retrospective cohort study

    by Kanit Bunnag, Arunchai Chang, Thanakarn Nuyim, Natthawat Sitthinamsuwan, Nataree Rujipattanapong, Kittiphan Chienwichai, Manus Rugivarodom, Sakkarin Chirapongsathorn, Varayu Prachayakul

    The clinical benefit of fresh frozen plasma (FFP) transfusion prior to endoscopy in patients with acute upper gastrointestinal bleeding (AUGIB) and mild coagulopathy remains uncertain. We evaluated the association between pre-endoscopic FFP transfusion and clinical outcomes in patients with AUGIB and an international normalized ratio (INR) of 1.5–2.5. We conducted a retrospective two-center cohort study including adult patients admitted with AUGIB and INR 1.5–2.5 at two tertiary referral hospitals in Thailand between 2016 and 2020. Patients were categorized according to receipt of pre-endoscopic FFP transfusion. Multivariable logistic regression analyses were performed using baseline covariates and bleeding severity scores. An exploratory composite in-hospital major adverse event endpoint was evaluated to improve model stability. Among 244 patients (158 received FFP; 86 did not), those receiving pre-endoscopic FFP had higher crude rates of 30-day all-cause mortality (23.4% vs. 11.6%), in-hospital mortality (24.1% vs. 7.0%), pulmonary edema (23.4% vs. 4.7%), and the composite in-hospital major adverse event endpoint (40.5% vs. 10.5%) (all p < 0.01). After multivariable adjustment, pre-endoscopic FFP transfusion remained associated with the composite endpoint (adjusted odds ratio [aOR] 5.28; 95% confidence interval [CI], 2.17–12.82), in-hospital mortality (aOR 5.36; 95% CI, 1.87–15.37), pulmonary edema (aOR 3.85; 95% CI, 1.21–12.26), and 30-day mortality (aOR 2.69; 95% CI, 1.09–6.66). In subgroup analyses, these associations were more consistent among patients with variceal bleeding. In patients with AUGIB and mildly elevated INR, pre-endoscopic FFP transfusion was associated with higher mortality and pulmonary complications, particularly in those with variceal bleeding. Given the retrospective design and potential for residual confounding, these findings should be interpreted with caution. Nevertheless, these findings support consideration of a more selective, context-based approach to plasma transfusion and highlight the need for prospective studies to inform evidence-based transfusion strategies.

  • Open Access

    Preprocedural Anxiety in Kidney Biopsy: A Prospective Study of Prevalence, Risk Factors, and Physiological Correlates

    by Kittiphan Chienwichai, Sirin Jiwakanon, Kamonrat Chaiviriyawong, Jananya Wattanakul, Thanapong Sungworawongpana, Sorawat Sangkaew, Arunchai Chang, Pannawat Mongkolrattanakul, Songklod Pakdeejit

    Background/Objectives: Despite the widespread recognition of preprocedural anxiety in awake invasive procedures, there is a paucity of data examining its prevalence and clinical impact in patients undergoing percutaneous kidney biopsy. This study aimed to determine the prevalence of preprocedural anxiety, assess its association with peri-procedural hemodynamic parameters, and identify factors associated with elevated anxiety. Methods: In this prospective observational study, 151 adults scheduled for percutaneous kidney biopsy between June 2023 and January 2025 were enrolled. Anxiety was assessed 24 h before the procedure using the Thai State–Trait Anxiety Inventory Y1 (STAI-Y1). Blood pressure and pulse rate were measured at baseline and 30 min before biopsy. Mixed-effects models evaluated associations between anxiety and hemodynamic changes, and logistic regression identified predictors of anxiety. Results: Clinically significant anxiety (STAI-Y1 ≥ 40) was present in 55% of patients, with 43.4% reporting very high anxiety. Anxiety status was not independently associated with changes in systolic or diastolic blood pressure or pulse rate. However, diastolic blood pressure increased significantly from baseline to preprocedural across all patients (mean increase 5.45 mmHg; p = 0.008), irrespective of anxiety. Higher serum creatinine (OR 1.29; p = 0.012) and a history of previous kidney biopsy (OR 4.28; p = 0.004) were independently associated with anxiety. Conclusions: Preprocedural anxiety is highly prevalent among patients undergoing kidney biopsy but does not independently influence peri-procedural hemodynamic parameters. Targeted screening and supportive interventions may benefit patients at increased risk of anxiety.

  • Open Access

    Association Between Ratio of Triglyceride to High-Density Lipoprotein Cholesterol and Cardiovascular and All-Cause Mortality in Non-Diabetic Hemodialysis Patients

    by Jane Pitanupong, Arunchai Chang, Apichai Wattanapisit

    This study examined whether the triglyceride-to-high-density lipoprotein cholesterol (TG/HDL-C) ratio is associated with cardiovascular and all-cause mortality among non-diabetic patients undergoing hemodialysis. From June 2017 to December 2023, patients followed until December 2024 were categorized into two groups based on their baseline TG/HDL-C ratio: those with a high TG/HDL-C ratio (>3.29) and those with a non-elevated TG/HDL-C ratio (≤3.29). The association between TG/HDL-C ratio and CV and all-cause mortality was examined by univariate and multivariate Cox regression analyses. Of the 138 patients, 43 were categorized into the high TG/HDL-C ratio group and 95 into the non-elevated TG/HDL-C ratio group. The non-elevated TG/HDL-C ratio group had significantly increased cardiovascular survival rates of 1, 3, and 5 years (97.8% vs. 85.2%, 96.2% vs. 70.0%, and 87.0% vs. 52.2%, respectively; p < 0.05) and overall survival rates of 1, 3, and 5 years (95.8% vs. 79.1%, 89.6% vs. 62.9%, and 73.9% vs. 40.7%, respectively; p < 0.05). In the proportional hazards model, a high TG-HDL ratio was an independent predictor of cardiovascular mortality (hazard ratio [HR]: 6.799; 95% confidence interval [CI]: 2.276–20.313; p = 0.001) and all-cause mortality (HR: 2.88; 95% CI: 1.16–7.17; p = 0.023). A high TG/HDL-C ratio was associated with CV and overall mortality in non-diabetic HD patients. Further research will be required to explore changes in the serum TG/HDL-C ratio, assess lipoprotein profiles, and determine their outcomes in this group.


  • One vs Five Days of Octreotide Infusion for Acute Esophageal Variceal Bleeding: A Randomized Controlled Trial

    by Sakkarin Chirapongsathorn, Arunchai Chang, Suppakorn Malikhao, Dhanusorn Wanichagool, Witsarut Manasirisuk, Uayporn Kaosombatwattana, Attapon Rattanasupar, Nuttida Polpanich, Phadet Noophun, Anuchit Suksamai, et al.

    INTRODUCTION: The optimal duration of octreotide infusion for esophageal variceal bleeding remains unclear. We aimed to compare the efficacy of 1-day vs 5-day octreotide infusion combined with endoscopic therapy, with the primary outcome of early (5-day) rebleeding under a noninferiority framework and secondary outcomes of 6-week rebleeding and all-cause mortality. METHODS: This nationwide, multicenter, noninferiority, open-label, randomized, controlled trial included 220 patients with cirrhosis and acute esophageal variceal bleeding who underwent endoscopic band ligation in 5 tertiary-care and 3 university-based hospitals across Thailand. They received a 1-day (n = 109) or 5-day (n = 111) regimen of continuous octreotide infusion after successful endoscopy. Rebleeding, transfusion requirements, and mortality were assessed. RESULTS: Most participants were men (180/220), and the average age was 56 years. The 5-day rebleeding (1.83% vs 1.80%, P ≥ 0.99), 6-week rebleeding (8.26% vs 10.81%, P = 0.52), and 6-week all-cause mortality (5.50% vs 6.31%, P = 0.80) rates were similar between the 1-day and 5-day groups. The event-rate difference in early rebleeding was 0.03%, indicating noninferiority (95% CI, 3.50%–3.56%). Patients in the 1-day group required significantly fewer blood transfusions and had a shorter time to oral diet and shorter hospital stay. DISCUSSION: After successful endoscopic band ligation, the 1-day regimen of octreotide had a noninferior effect compared with the standard 5-day regimen in the prevention of 5-day rebleeding and exhibited no significant differences in the prevention of 6-week rebleeding and all-cause mortality. Trial registration number: Thai Clinical Trials Registry, TCTR 20221004008.


  • Open Access

    Urine Electrolyte to Predict Treatment Failure of Fluid Restriction in Syndrome of Inappropriate Antidiuresis

    by Kittiphan Chienwichai, Sirin Jiwakanon, Kamonrat Chaiviriyawong, Jananya Wattanakul, Warat Rojnsaengroung, Soravit Manasuth, Sorawat Sangkaew, Arunchai Chang, Pannawat Mongkolrattanakul

    Key Points: The Furst equation helps identify patients at risk of fluid restriction failure in syndrome of inappropriate antidiuresis, although its predictive performance is limited. Additional urinary biomarkers beyond the Furst equation may not improve the prediction of fluid restriction response. Background: The syndrome of inappropriate antidiuresis (SIAD) is a common cause of hyponatremia in hospitalized patients, with fluid restriction (FR) as the first-line treatment. However, up to 50% of patients fail to respond to FR, highlighting the need for reliable predictors of treatment failure. Therefore, this study aimed to evaluate the predictive performance of urinary biomarkers, including the Furst equation (the ratio of the sum of urinary sodium and potassium concentrations to plasma sodium), urine osmolality, and urine output, in identifying nonresponders to FR. Methods: This prospective multicenter cohort study was conducted at two medical centers in Thailand from September 2022 to June 2024 and included 79 hospitalized patients with SIAD. Response to FR was defined as an increase in serum sodium level of ≥3 mEq/L by day 4, with no decrease in serum sodium levels at any point during the FR period. Predictive performance was assessed using sensitivity, specificity, and area under the receiver operating characteristic curve (AUC) for each biomarker. Multivariable logistic regression analysis incorporating all urinary biomarkers was also performed. Results: Overall, 59% of patients failed to respond to FR by day 4, and adherence to FR was modest (72%). The Furst equation demonstrated the best predictive performance, with an optimal cutoff of 0.86 (sensitivity: 55.3%; specificity: 70.2%, AUC: 0.65). Combining the Furst equation with urine osmolality and urine output improved specificity to 91.0%, although sensitivity decreased to 32.3%. A multivariable logistic regression model achieved similar discrimination (AUC: 0.67) compared with the Furst equation alone. Conclusions: Although the Furst equation can identify nonresponders to FR, its predictive performance is limited. Our findings suggest that other urinary biomarkers beyond the Furst equation may not improve overall predictive accuracy for predicting nonresponse to FR. These findings highlight the need for more effective predictive tools. Further studies are warranted to validate these results and optimize treatment strategies for SIAD. Clinical Trial registry name and registration number: Thai Clinical Trials Registry, TCTR20221206001.


  • Open Access

    Impact of dosing strategy on clinical outcomes of patients with lupus nephritis initially treated with lower-than-recommended-dose cyclophosphamide

    by Kittiphan Chienwichai, Aniwat Choomnirat, Sorawat Sangkaew, Nutthapong Sunanthamethee, Arunchai Chang


  • Open Access

    Impact of pre-sarcopenia on outcomes of transarterial chemoembolization in unresectable hepatocellular carcinoma

    by Attapon Rattanasupar, Tanaporn Prateepchaiboon, Keerati Akarapatima, Apiradee Songjamrat, Songklod Pakdeejit, Arunchai Chang

    Sarcopenia’s impact on hepatocellular carcinoma (HCC) outcomes is well-documented, but the effects of pre-sarcopenia remain unclear. This study investigates the impact of pre-sarcopenia on tumor response and survival in patients with unresectable HCC undergoing transarterial chemoembolization (TACE). We retrospectively evaluated muscle volume using the SliceOmatic software in patients with unresectable HCC treated with TACE. Pre-sarcopenia was defined by Japan Society of Hepatology standards (men: 42 cm2/m2; women: 38 cm2/m2). Pre-sarcopenia and non-pre-sarcopenia groups were compared, and Cox proportional hazards model was used to identify survival-influencing variables. Subgroup analysis was conducted stratified by the tumor burden, using serum alpha-fetoprotein (AFP) levels at a diagnostic cutoff value of 200 ng/mL. Of the 100 patients, 39 had pre-sarcopenia. The presence of pre-sarcopenia was not associated with tumor complete response achievement. The median overall survival (OS) was significantly lower in the pre-sarcopenia group (18 months) than in the non-pre-sarcopenia group (30 months; log-rank P = 0.039). Subgroup analysis among 77 patients with AFP < 200 ng/mL revealed that OS was particularly poor in the pre-sarcopenia group (16 vs. 34 months; log-rank P < 0.001). Multivariate analysis identified increased AFP (adjusted hazard ratio [HR] per 10-unit increase 1.142; P < 0.001), higher Model for End-Stage Liver Disease score (adjusted HR per 1-unit increase 1.176; P < 0.001), and pre-sarcopenia (adjusted HR 2.965; P < 0.001) as predictors of shorter OS. Pre-sarcopenia is a significant predictor of increased mortality in patients with unresectable HCC undergoing TACE, especially in those with AFP < 200 ng/mL, suggesting its potential as a target for early intervention.